Hormone treatment of meningiomas: Lack of response to medroxyprogesterone acetate (MPA)
- 47 Downloads
Medroxyprogesterone acetate (MPA) has been used in high doses as hormone treatment for metastatic breast cancer. We treated five intracranial meningiomas with MPA expecting that MPA would reduce the volume or decrease the growth rate. All five patients were postmenopausal women, aged 47 to 73 years. Before treatment, the growth rate of each tumour was assessed by two consecutive CT scans (CT 1 and CT 2). Tumours 1 to 4, histologically benign meningiomas, grew slowly as the tumour volumes were not found to increase in 21 to 45 months between CT 1 and CT 2. Tumour 5 was an anaplastic meningioma the rapid growth of which was evident in 8 weeks between CT 1 and CT 2. After CT 2, MPA was given 1,000 mg intramusculary once weekly for 17 to 29 weeks until CT 3 which showed the response. Tumours 1 to 4 had neither reduced in volume nor developed necroses, and tumour 5 continued its fast growth at the same rate as before.
KeywordsMeningioma medroxyprogesterone acetate hormone treatment growth rate CT scan
Unable to display preview. Download preview PDF.
- 10.Hinton, D., Mobbs, E. G., Sima, A. A., Hanna, W., Steroid receptors in meningiomas. A histochemical and biochemical study. Acta Neuropathol. (Berl.)62 (1983), 134–140.Google Scholar
- 12.Inoue, H., Tamamura, M., Koizumi, H., Nakamura, M., Naganuma, H., Ohye, C., Clinical pathology of malignant meningiomas. Acta Neurochir. (Wien)73 (1984), 179–191.Google Scholar
- 17.Magdelenat, H., Pertuiset, B. F., Poisson, M., Martin, P. M., Philippon, J., Pertuiset, B., Buge, A., Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases. Acta Neurochir. (Wien)64 (1982), 199–213.Google Scholar
- 19.Markwalder, T.-M., Seiler, R. W., Zava, D. T., Endocrine manipulation of inoperable and recurrent meningiomas—a pilot study. In: Proceedings of the 13th International Congress of Chemotherapy (Spitzyet al., eds.). Vienna: Verlag H. Egermann. 1983.Google Scholar
- 20.Martin, F., Adlercreutz, H., Aspects of megestrol acetate and medroxyprogesterone acetate metabolism. In: Pharmacology of Steroid Contraceptive Drugs (Garattiniet al., eds.), pp. 99–115. New York: Raven Press. 1977.Google Scholar
- 23.Mattsson, W., High dose medroxyprogesterone-acetate treatment in advanced mammary carcinoma. A phase II investigation. Acta Radiol. Oncol.17 (1978), 387–400.Google Scholar
- 28.Pannuti, F., Martoni, A., DiMarco, A. R.,et al., Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Europ. J. Cancer15 (1979), 593–601.Google Scholar
- 29.Pertuiset, B., Farah, S., Clayes, L., Goutorbe, J., Metzger, J., Kujas, M., Operability of intracranial meningiomas. Personal series of 353 cases. Acta Neurochir. (Wien)76 (1985), 2–11.Google Scholar
- 33.Simpson, D., The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatry20 (1957), 22–39.Google Scholar